These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8081414)

  • 41. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
    Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
    Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis.
    Siddons MA; Pickering-Brown SM; Mann DM; Owen F; Cooper PN
    Neurosci Lett; 1996 Apr; 208(1):65-8. PubMed ID: 8731176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
    Huang J; Chuang SK; Cheng CL; Lai ML
    Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
    Ford GA; Wood SM; Daly AK
    Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel mutations of CYP3A4 in Chinese.
    Hsieh KP; Lin YY; Cheng CL; Lai ML; Lin MS; Siest JP; Huang JD
    Drug Metab Dispos; 2001 Mar; 29(3):268-73. PubMed ID: 11181494
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
    Yokoi T; Kamataki T
    Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
    Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
    J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
    Løvlie R; Daly AK; Molven A; Idle JR; Steen VM
    FEBS Lett; 1996 Aug; 392(1):30-4. PubMed ID: 8769309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
    Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
    [TBL] [Abstract][Full Text] [Related]  

  • 52. R296C and other CYP2D6 mutations in Chinese.
    Wang SL; Lai MD; Lai ML; Huang JD
    Pharmacogenetics; 1995 Dec; 5(6):385-8. PubMed ID: 8747410
    [No Abstract]   [Full Text] [Related]  

  • 53. Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan.
    Chen CH; Hung CC; Wei FC; Koong FJ
    Psychiatr Genet; 2001 Sep; 11(3):153-5. PubMed ID: 11702057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
    Beyeler C; Daly AK; Armstrong M; Astbury C; Bird HA; Idle JR
    J Rheumatol; 1994 Jun; 21(6):1034-9. PubMed ID: 7932410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.
    Marez D; Sabbagh N; Legrand M; Lo-Guidice JM; Boone P; Broly F
    Pharmacogenetics; 1995 Oct; 5(5):305-11. PubMed ID: 8563771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
    Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
    Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
    Tamminga WJ; Wemer J; Oosterhuis B; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2001 Dec; 57(10):717-22. PubMed ID: 11829201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
    Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses.
    Varela N; Quiñones LA; Stojanova J; Garay J; Cáceres D; Cespedes S; Sasso J; Miranda C
    Pharmacol Res; 2015 Nov; 101():124-9. PubMed ID: 26211952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.